ArticleMicrobiology spectrum2026
Six-year retrospective comparison of GeneXpert MTB/RIF Ultra PCR and culture for pediatric tuberculosis diagnosis in non-sputum samples.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lungs Are Only Half the Story: Programmatic Shifts to Prioritize Pediatric Extrapulmonary Tuberculosis Detection in High-Burden Settings.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosing tuberculosis (TB) in children is challenging due to the paucibacillary nature of the disease and difficulty in obtaining sputum samples. This 6-year retrospective study compared the diagnostic performance of the GeneXpert MTB/RIF Ultra PCR (GX-MTB/R-U) assay, an improved version of the MTB/RIF PCR (GX-MTB/R) assay, with conventional mycobacterial culture in pediatric non-sputum samples. A total of 417 non-sputum samples from a tertiary pediatric facility underwent simultaneous GX-MTB/R-U and culture testing. Performance was evaluated using conventional culture as a gold standard, and clinical review was used to resolve discordant results. GX-MTB/R-U demonstrated 93.9% sensitivity and 97.9% specificity when culture was used as the gold standard. Eight samples positive by GX-MTB/R-U assay but negative by culture were confirmed as true positive using clinical review of the patients, increasing the sensitivity to 95.1% and specificity to 100%. GX-MTB/R-U demonstrated excellent diagnostic performance in comparison to conventional culture and microscopy, particularly for paucibacillary and extrapulmonary samples. Our study results support the use of GX-MTB/R-U assay as a frontline diagnostic tool in pediatric TB, with culture reserved for confirmation of negative PCR results and antibiotic susceptibility testing.IMPORTANCEDelays or inaccuracies in tuberculosis (TB) diagnosis can lead to treatment delays, disease progression, and poor clinical outcomes. This study provides compelling evidence on the excellent diagnostic performance of the GeneXpert MTB/RIF Ultra (GX-MTB/R-U) assay in pediatric non-sputum samples compared to conventional culture, the current gold standard. By demonstrating high sensitivity and specificity, particularly in extrapulmonary samples, the findings of our study highlight the potential of GX-MTB/R-U as a frontline TB diagnostic tool. The use of this assay in clinical practice could improve early detection, ensure timely initiation of antibiotic treatment, ultimately improving pediatric TB management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.